Investor in pioneering radical longevity startups

Developing a platform to rejuvenate and bank hematopoietic stem cells and as a result reboot the immune system. Advancing to phase I trials for chemotherapy patients.

Advancing USP30 inhibitors to trigger mitophagy and enhanced mitochondrial health with a robust science driven approach. These small molecules have the potential to address aging and neurodegeneration.

Accelerating protein engineering with an automated laboratory platform that reduces cost and time for designers. Working with industry leaders Adaptyv is set to lead the growing protein design market.

Aiming to become the 'Function Health' of Europe by delivering data-driven, personalized longevity insights and interventions to the mainstream.